Docteur EMILIE SHIPLEY

Bibliographie

• Rheumatic and musculoskeletal disorders in musicians: risks, adaptations and management

  2025

  ArticleRMD Open

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  2021

  ArticleRheumatology and Therapy

• Role of stress in the development of rheumatoid arthritis: a case–control study

  2021

  ArticleRheumatology

• Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy

  2019

  ArticleArthritis Research and Therapy

• Identification and Characterization of A Synovial Fluid Microbial DNA in Rheumatoid Arthritis Patients

  2014

  CongrèsAnnual European Congress of Rheumatology

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Lieu de consultation

• CENTRE HOSPITALIER DAX

  51 Boulevard YVES DU MANOIR, 40107 Dax

  ☎ 0558914848Hospitalier🏥 Centre CH ↗🏥 Voir cet établissement

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy

  Arthritis research & therapy · 2019

  📚 58 citations🎯 RCR 3.25Top 14% NIH🔓 Open Access📄 PDF gratuit ↗
• 2

  IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus

  Arthritis & rheumatology (Hoboken, N.J.) · 2016

  📚 21 citations

  Lire l'abstract Crossref ↓

  ObjectivePlasmacytoid dendritic cells (PDCs) play a central role in pathogenesis of systemic lupus erythematosus (SLE) through their unique ability to produce large amounts of type I interferon (IFN) upon Toll‐like receptor 7 (TLR‐7) and TLR‐9 triggering. PDCs express specific surface regulatory receptors involved in negative regulation of IFNα secretion. These receptors use the γ‐chain of high‐affinity Fc receptor (FcR) for IgE, FcɛRI. We undertook this study to test our hypothesis that IgE engagement of FcɛRI on PDCs may impact IFNα production in SLE patients.MethodsSerum levels of total IgE were measured in healthy volunteers, SLE patients, and patients with IgE‐dependent allergic disorders. FcɛRI expression on PDCs from SLE patients was evaluated by flow cytometry. Purified PDCs were incubated with monoclonal IgE for 24 hours, then stimulated for 18 hours with TLR agonists or immune complexes (ICs). IFNα production by PDCs was detected by quantitative real‐time polymerase chain reaction (PCR) and enzyme‐linked immunosorbent assay. Expression of TLR‐7, TLR‐9, and IFN regulatory factor 7 (IRF‐7) in PDCs was quantified by quantitative real‐time PCR.ResultsWe observed significantly higher IgE levels in SLE patients with quiescent disease than in those with active disease. In SLE patients, IgE levels correlated inversely with disease activity. IgE levels were not associated with the presence of antinuclear IgE. Purified PDCs treated for 24 hours with monoclonal IgE up‐regulated FcɛRI expression in an IgE dose–dependent manner. IgE‐treated PDCs significantly decreased IFNα secretion and down‐regulated CCR7 expression upon stimulation with TLR‐7 and TLR‐9 ligands and ICs from lupus patients. IgE treatment down‐regulated expression of TLR‐9 and IRF‐7.ConclusionOur results support the notion that IgE plays a protective role in SLE pathogenesis through the modulation of inflammatory response by PDCs.

• 3

  Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study)

  Frontiers in medicine · 2021

  📚 20 citations🎯 RCR 1.81🔓 Open Access

  Lire l'abstract Crossref ↓

  Background: Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting.Methods: Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment. Patient characteristics and journey, diagnostic methods and treatments were collected. Descriptive analyses were performed.Results: In total, 306 patients (67% females, mean age 74 ± 8 years old) were recruited by 69 physicians (internists: 85%, rheumatologists: 15%); 13% of patients had newly diagnosed GCA (diagnosis-to-visit interval <6 weeks). Overall median disease duration was 13 months (interquartile range 5–26). Most patients were referred by general practitioners (56%), then ophthalmologists (10%) and neurologists (7%). Most common comorbidities were hypertension (46%), psychiatric disorders (10%), dyslipidemia (12%), diabetes (9%), and osteoporosis (6%). Initial GCA presentations included cranial symptoms (89%), constitutional symptoms (74%), polymyalgia rheumatica (48%), and/or other extra-cranial manifestations (35%). Overall, 85, 31, 26, and 30% of patients underwent temporal artery biopsy, high-resolution temporal artery Doppler ultrasonography, 18FDG-PET, and aortic angio-CT, respectively. All patients received glucocorticoids, which were ongoing for 89%; 29% also received adjunct medication(s) (methotrexate: 19%, tocilizumab: 15%). A total of 40% had relapse(s); the median time to the first relapse was 10 months. Also, 37% had comorbidity(ies) related to or aggravated by glucocorticoids therapy.Conclusion: This large observational study provides insight into current medical practices for GCA. More than one third of patients had comorbidities related to glucocorticoid therapy for a median disease duration of 13 months. Methotrexate and tocilizumab were the most common adjunct medications.

Publications scientifiques (12) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Datasets & protocoles partagés

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  Audiovisual2020Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online

• Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study

  Audiovisual2020Adis Journals

  <strong>Article full text</strong> <br> The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online

Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).

Partager cette fiche